COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Rosuvastatin Efficacy and Safety Evaluation in Hypercholesterolaemic Patients (RESEARCH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00695539
Recruitment Status : Completed
First Posted : June 12, 2008
Last Update Posted : October 5, 2009
Information provided by:

Brief Summary:
This is a single-arm, phase IV, open-label, prospective, non interventional study to evaluate the efficacy, tolerability and safety of rosuvastatin administered for 24 weeks in approximately 900 Greek subjects with hypercholesterolemia under normal clinical practice.

Condition or disease

Layout table for study information
Study Type : Observational
Actual Enrollment : 810 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: A Multi-centre, Open Label, Non-randomised, Non Interventional, 24 Weeks Study for the Efficacy and Safety of Rosuvastatin Following Its Administration in Real Life Clinical Practice in Greek Hypercholesterolaemic Patients
Study Start Date : December 2007
Actual Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. The assessment of rosuvastatin efficacy in the reduction of low-density lipoprotein cholesterol (LDL-C) in subjects with hypercholesterolemia at week 12 of treatment compared with baseline [ Time Frame: At 12 weeks of treatment ]
  2. To evaluate the percentage of patients on European LDL-C target at week 12 [ Time Frame: At 12 weeks of treatment ]

Secondary Outcome Measures :
  1. Changes in HDL-C, TC and TG [ Time Frame: At week 12 & 24 of treatment ]
  2. Safety and tolerability [ Time Frame: Throughout the study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Primary Care

Inclusion Criteria:

  • Patients with hypercholesterolaemia who are already in treatment with rosuvastatin according to the approved SPC for no longer than 1 month prior to study entry
  • Patients that are able to read, understand and sign the Patient Information & Consent Form
  • Patients that are willing to comply with all study requirements

Exclusion Criteria:

  • Patients that are likely not to comply with all study requirements
  • Patients that currently participate or have participated in a 3 months period prior to study entry in another clinical trial
  • Female of child bearing potential that do not use a reliable method of contraception. Pregnancy or lactation.
  • Patients that meet any of the contraindications described in the approved SPC

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00695539

Layout table for location information
Research Site
Alexandroupoli, Greece
Research Site
Athens, Greece
Research Site
Iraklio, Crete, Greece
Research Site
Larissa, Greece
Research Site
Rio, Patra, Greece
Research Site
Thessaloniki, Greece
Sponsors and Collaborators

Layout table for additonal information
Responsible Party: Panagiotis Pontikis, MD, Medical & Regulatory Affairs Director, AstraZeneca Greece, AstraZeneca S.A., Greece Identifier: NCT00695539    
Other Study ID Numbers: NIS-CGR-CRE-2007/1
First Posted: June 12, 2008    Key Record Dates
Last Update Posted: October 5, 2009
Last Verified: October 2009
Keywords provided by AstraZeneca:
Additional relevant MeSH terms:
Layout table for MeSH terms
Lipid Metabolism Disorders
Metabolic Diseases
Rosuvastatin Calcium
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors